Taima Kageaki, Tanaka Hisashi, Tanaka Yoshihito, Itoga Masamichi, Takanashi Shingo, Tasaka Sadatomo
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Japan.
Intern Med. 2017 Sep 1;56(17):2321-2324. doi: 10.2169/internalmedicine.8445-16. Epub 2017 Aug 10.
Crizotinib, which is effective in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer, is sometimes associated with the generation of complex renal cysts. A 56-year-old man with ALK positive adenocarcinoma received crizotinib. Ten months after the introduction of crizotinib, a cystic lesion developed from his right kidney to the iliopsoas muscle, accompanied by fever, anemia, and hypoproteinemia. After 17 months of treatment, crizotinib was switched to alectinib, followed by the recovery of hypoproteinemia and systemic inflammation. Switching to alectinib may be beneficial in patients demonstrating crizotinib-associated complex renal cysts with systemic inflammation and exhaustion.
克唑替尼对间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌患者有效，但有时会与复杂性肾囊肿的产生有关。一名56岁的ALK阳性腺癌男性患者接受了克唑替尼治疗。在使用克唑替尼10个月后，其右肾至髂腰肌出现囊性病变，并伴有发热、贫血和低蛋白血症。治疗17个月后，将克唑替尼换为阿来替尼，随后低蛋白血症和全身炎症得到缓解。对于出现克唑替尼相关复杂性肾囊肿并伴有全身炎症和消耗的患者，换用阿来替尼可能有益。
